| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -47,056 | -32,875 |
| Stock-based compensation expense | 6,162 | 3,973 |
| Depreciation | 504 | - |
| Non-cashinterest expense related to term loan | 554 | 362 |
| Depreciation and amortization | - | 340 |
| Non-cashlease expense | 577 | 382 |
| Non-cash research and development license expense | 0 | 0 |
| Loss on disposal of assets | -156 | -42 |
| Change in other, net | 236 | 124 |
| Loss on extinguishment of debt | -681 | -681 |
| Prepaid expenses and other assets | 555 | 1,183 |
| Accounts payable | 518 | 57 |
| Accrued liabilities and other liabilities | -2,030 | -2,238 |
| Net cash used in operating activities | -40,253 | -30,335 |
| Capital expenditures | 24 | 24 |
| Net cash used in investing activities | -24 | -24 |
| Proceeds from issuance of common stock from initial public offering | 0 | 0 |
| Payments on issuance costs-IPO | 0 | 0 |
| Payments on issuance cost from registration statement | 556 | 556 |
| Proceeds from issuance of term loan, net | 19,688 | 19,688 |
| Repayment of former term loan | 10,213 | 10,213 |
| Payment of loan financing cost | 127 | 127 |
| Payments on issuance costs-Series CPreferred Stock Financing | 0 | 0 |
| Proceeds from exercise of stock options | 351 | 198 |
| Proceeds from convertible grant agreement | 750 | 750 |
| Net cash provided by financing activities | 9,893 | 9,740 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -29 | -25 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -30,413 | -20,644 |
| Cash and cash equivalents at beginning of period | 168,729 | - |
| Cash and cash equivalents at end of period | 138,316 | - |
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)